AACR 2012: AZD3514 in Prostate Cancer

The 2012 annual meeting of the American Association for Cancer Research (AACR) provided a window into the world of new cancer drugs in early development. One that caught my attention in prostate cancer was AstraZeneca's AZD3514, a first-in-class Androgen Receptor down-regulator (SARD).

1,844 total views
  1. Pieter Droppert writes the Biotech Strategy Blog and this Storify is part of a series of blog posts on the 2012 annual meeting of the American Association for Cancer Research (AACR).
Like
Share

Share

Facebook
Google+